Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE · Real-Time Price · USD
13.62
-0.46 (-3.27%)
Mar 12, 2026, 10:23 AM EDT - Market open
Wave Life Sciences Revenue
In the year 2025, Wave Life Sciences had annual revenue of $42.73M, down -60.55%. Wave Life Sciences had revenue of $17.25M in the quarter ending December 31, 2025, a decrease of -40.65%.
Revenue (ttm)
$42.73M
Revenue Growth
-60.55%
P/S Ratio
62.04
Revenue / Employee
$134,785
Employees
317
Market Cap
2.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 42.73M | -65.58M | -60.55% |
| Dec 31, 2024 | 108.30M | -5.00M | -4.42% |
| Dec 31, 2023 | 113.31M | 109.66M | 3,005.10% |
| Dec 31, 2022 | 3.65M | -37.32M | -91.09% |
| Dec 31, 2021 | 40.96M | 24.98M | 156.30% |
| Dec 31, 2019 | 15.98M | 1.57M | 10.89% |
| Dec 31, 2018 | 14.41M | 10.52M | 270.25% |
| Dec 31, 2017 | 3.89M | 3.74M | 2,461.18% |
| Dec 31, 2015 | 152.00K | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Apellis Pharmaceuticals | 1.00B |
| Telix Pharmaceuticals | 803.79M |
| Travere Therapeutics | 490.73M |
| Arcus Biosciences | 247.00M |
| Beam Therapeutics | 139.74M |
| Viridian Therapeutics | 70.85M |
| Tango Therapeutics | 62.38M |
| Immunome | 6.94M |
WVE News
- 5 days ago - FDA reversals leave investors worrying about the fates of other experimental drugs - CNBC
- 7 days ago - Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference - GlobeNewsWire
- 13 days ago - Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 17 days ago - Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 21 days ago - Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026 - GlobeNewsWire
- 5 weeks ago - Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path - Benzinga
- 5 weeks ago - Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency - GlobeNewsWire